^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    davutamig (REGN5093)

    i
    Other names: REGN5093
    Company:
    Regeneron
    Drug class:
    c-MET inhibitor
    Related drugs:
    4ms
    Engineering hydrophobicity and manufacturability for optimized biparatopic antibody-drug conjugates targeting c-MET. (PubMed, MAbs)
    The resulting biparatopic anti-c-MET ADCs were comparably active on c-MET expressing tumor cell lines as REGN5093 exatecan DAR6 ADC. Structural molecular modeling of paratope combinations for preferential inter-target binding combined with protein engineering for manufacturability yielded deep insights into the capabilities of rational and library approaches. The methodologies of in silico hydrophobicity identification and sequence optimization could serve as a blueprint for rapid development of optimal biparatopic ADCs targeting further tumor-associated antigens in the future.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET expression
    |
    davutamig (REGN5093)
    10ms
    Predictive Biomarkers of Response to REGN5093 to Guide Patient Selection in MET-Altered Advanced Non-small Cell Lung Cancer (IASLC-WCLC 2023)
    We report biomarkers associated with clinical response and resistance to REGN5093 which may help with screening of aNSCLC pts in future combination studies of REGN5093 with other therapies.
    Clinical • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • JAK2 (Janus kinase 2)
    |
    EGFR mutation • BRAF mutation • MET amplification • KRAS G12D • PIK3CA H1047R • MET exon 14 mutation • MET overexpression • MET mutation • MET expression • KRAS G12 • JAK2 V617F • TP53 R248Q • EGFR mutation + MET-CEP7 fusion • MET Y1230C • MET D1228H • MET Y1230C
    |
    FoundationOne® CDx • TruSight Oncology 500 Assay
    |
    davutamig (REGN5093)
    1year
    REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=82, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET elevation
    |
    davutamig (REGN5093)
    over2years
    REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=111, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Nov 2023 --> Oct 2024 | Trial primary completion date: Nov 2023 --> Oct 2024
    Clinical • Trial completion date • Trial primary completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET mutation • MET expression
    |
    davutamig (REGN5093)
    over3years
    REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=111, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Feb 2024 --> Nov 2023 | Trial primary completion date: Feb 2024 --> Nov 2023
    Clinical • Trial completion date • Trial primary completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET mutation • MET expression
    |
    davutamig (REGN5093)
    4years
    [VIRTUAL] A phase I/II study of REGN5093, a MET x MET bispecific antibody, in patients with MET-altered advanced non-small cell lung cancer (NSCLC). (ASCO 2020)
    The study is currently open for enrollment. Research Funding: Regeneron Pharmaceutical, Inc.
    Clinical • P1/2 data
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • HGF (Hepatocyte growth factor) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET overexpression • MET mutation • MET expression
    |
    davutamig (REGN5093)